Coronavirus has impacted the global Economy, due to which the domestic equity faced a huge decline. Most stocks have been hit low records. The BSE Sensex and NSE Nifty had their worst run since the 2nd week of March. On 18th March, Sensex ended at 28,896 points by falling 1709 points while Nifty failed below 8500 points.

In the midst of the mayhem, the pharma sector looks less affected as it is profiting handsomely. Investors hunting for safe havens in the ongoing turmoil can consider Investing in the pharma sector as it is showing an improving trend in Earnings.
In recent years, the pharmaceutical sector has augmented as the new listing of hospitals and diagnostic companies have been added more to the basket. The government policies and rising Income levels are giving robust growth in this sector.
The pharmaceutical sector was valued at US$33 billion in 2017. In 2018, the Indian pharmaceutical exports stood at US$17.27 billion and reached US$19.14 billion in 2019. The pharmaceutical Industry is anticipated to expand at a CAGR of 22.4% by 2020.
Indian companies received 304 Abbreviated New Drug Application from the US Food and Drug Administration in 2017. The pharma sector will expand and will reach US$55 billion by 2025.
The pharmaceuticals exports bulk drugs, intermediates, drug formulations, biologicals, herbal products and so on. India’s biotechnology industry compromising bio-agriculture, bio-industry, bio-pharmaceuticals and so on is expected to grow at the moderate rate of around 30% a year and it is expected to reach US$ 100 billion in the coming years.
The pharma sector provides several opportunities for investments and trade due to the following factors:
(Erstwhile SBI Pharma Fund) To provide the investors maximum growth opportunity through equity
investments in stocks of growth oriented sectors of the economy. Below is the key information for SBI Healthcare Opportunities Fund Returns up to 1 year are on The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. Research Highlights for Nippon India Pharma Fund Below is the key information for Nippon India Pharma Fund Returns up to 1 year are on (Erstwhile UTI Pharma & Healthcare Fund) The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors. Research Highlights for UTI Healthcare Fund Below is the key information for UTI Healthcare Fund Returns up to 1 year are on Fund NAV Net Assets (Cr) 3 MO (%) 6 MO (%) 1 YR (%) 3 YR (%) 5 YR (%) 2025 (%) SBI Healthcare Opportunities Fund Growth ₹507.077
↑ 2.79 ₹5,870 -0.8 15.4 16 23.3 18 -3.5 Nippon India Pharma Fund Growth ₹555.236
↑ 2.86 ₹9,166 -2.7 7.4 8.1 17.5 13.2 -3.3 UTI Healthcare Fund Growth ₹328.616
↓ -0.45 ₹1,430 -1.6 12.3 12.4 22.3 15.1 -3.1 Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 30 Oct 26 Research Highlights & Commentary of 3 Funds showcased
Commentary SBI Healthcare Opportunities Fund Nippon India Pharma Fund UTI Healthcare Fund Point 1 Lower mid AUM (₹5,870 Cr). Highest AUM (₹9,166 Cr). Bottom quartile AUM (₹1,430 Cr). Point 2 Established history (21+ yrs). Established history (22+ yrs). Oldest track record among peers (27 yrs). Point 3 Top rated. Rating: 2★ (lower mid). Rating: 1★ (bottom quartile). Point 4 Risk profile: High. Risk profile: High. Risk profile: High. Point 5 5Y return: 17.98% (upper mid). 5Y return: 13.17% (bottom quartile). 5Y return: 15.06% (lower mid). Point 6 3Y return: 23.33% (upper mid). 3Y return: 17.50% (bottom quartile). 3Y return: 22.28% (lower mid). Point 7 1Y return: 15.96% (upper mid). 1Y return: 8.10% (bottom quartile). 1Y return: 12.39% (lower mid). Point 8 Alpha: 3.63 (upper mid). Alpha: -2.12 (bottom quartile). Alpha: 0.86 (lower mid). Point 9 Sharpe: 0.95 (upper mid). Sharpe: 0.57 (bottom quartile). Sharpe: 0.78 (lower mid). Point 10 Information ratio: 0.10 (upper mid). Information ratio: -1.17 (bottom quartile). Information ratio: 0.06 (lower mid). SBI Healthcare Opportunities Fund
Nippon India Pharma Fund
UTI Healthcare Fund
1. SBI Healthcare Opportunities Fund
SBI Healthcare Opportunities Fund
Growth Launch Date 31 Dec 04 NAV (30 Oct 26) ₹507.077 ↑ 2.79 (0.55 %) Net Assets (Cr) ₹5,870 on 30 Sep 26 Category Equity - Sectoral AMC SBI Funds Management Private Limited Rating ☆☆ Risk High Expense Ratio 1.93 Sharpe Ratio 0.95 Information Ratio 0.1 Alpha Ratio 3.63 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-15 Days (0.5%),15 Days and above(NIL) Growth of 10,000 investment over the years.
Date Value 31 Oct 21 ₹10,000 31 Oct 22 ₹10,166 31 Oct 23 ₹12,129 31 Oct 24 ₹19,105 31 Oct 25 ₹19,589 31 Oct 26 ₹22,856 Returns for SBI Healthcare Opportunities Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 30 Oct 26 Duration Returns 1 Month 0.2% 3 Month -0.8% 6 Month 15.4% 1 Year 16% 3 Year 23.3% 5 Year 18% 10 Year 15 Year Since launch 15.4% Historical performance (Yearly) on absolute basis
Year Returns 2025 -3.5% 2024 42.2% 2023 38.2% 2022 -6% 2021 20.1% 2020 65.8% 2019 -0.5% 2018 -9.9% 2017 2.1% 2016 -14% Fund Manager information for SBI Healthcare Opportunities Fund
Name Since Tenure Tanmaya Desai 1 Jun 11 15.35 Yr. Data below for SBI Healthcare Opportunities Fund as on 30 Sep 26
Equity Sector Allocation
Sector Value Health Care 88.34% Basic Materials 7.2% Asset Allocation
Asset Class Value Cash 4.47% Equity 95.53% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Dec 17 | SUNPHARMA11% ₹654 Cr 3,600,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB8% ₹465 Cr 500,000 Acutaas Chemicals Ltd (Basic Materials)
Equity, Since 30 Jun 24 | 5433495% ₹295 Cr 900,000 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 31 Jan 26 | APOLLOHOSP4% ₹261 Cr 320,000 Torrent Pharmaceuticals Ltd (Healthcare)
Equity, Since 30 Jun 21 | TORNTPHARM4% ₹259 Cr 540,000 Cipla Ltd (Healthcare)
Equity, Since 31 May 26 | 5000874% ₹258 Cr 1,920,000 Laurus Labs Ltd (Healthcare)
Equity, Since 31 Aug 23 | 5402224% ₹238 Cr 1,200,000 Max Healthcare Institute Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Mar 21 | MAXHEALTH4% ₹223 Cr 2,400,000 Aurobindo Pharma Ltd (Healthcare)
Equity, Since 31 Mar 26 | AUROPHARMA3% ₹201 Cr 1,200,000
↓ -118,192 Aster DM Quality Care Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Mar 24 | ASTERDM3% ₹188 Cr 2,700,000 2. Nippon India Pharma Fund
Nippon India Pharma Fund
Growth Launch Date 5 Jun 04 NAV (30 Oct 26) ₹555.236 ↑ 2.86 (0.52 %) Net Assets (Cr) ₹9,166 on 30 Sep 26 Category Equity - Sectoral AMC Nippon Life Asset Management Ltd. Rating ☆☆ Risk High Expense Ratio 1.81 Sharpe Ratio 0.57 Information Ratio -1.17 Alpha Ratio -2.12 Min Investment 5,000 Min SIP Investment 100 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value 31 Oct 21 ₹10,000 31 Oct 22 ₹9,688 31 Oct 23 ₹11,389 31 Oct 24 ₹17,209 31 Oct 25 ₹17,119 31 Oct 26 ₹18,563 Returns for Nippon India Pharma Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 30 Oct 26 Duration Returns 1 Month -0.8% 3 Month -2.7% 6 Month 7.4% 1 Year 8.1% 3 Year 17.5% 5 Year 13.2% 10 Year 15 Year Since launch 19.6% Historical performance (Yearly) on absolute basis
Year Returns 2025 -3.3% 2024 34% 2023 39.2% 2022 -9.9% 2021 23.9% 2020 66.4% 2019 1.7% 2018 3.6% 2017 7.6% 2016 -10.6% Fund Manager information for Nippon India Pharma Fund
Name Since Tenure Sailesh Raj Bhan 1 Apr 05 21.51 Yr. Kinjal Desai 25 May 18 8.36 Yr. Amber Singhania 11 Mar 26 0.56 Yr. Data below for Nippon India Pharma Fund as on 30 Sep 26
Equity Sector Allocation
Sector Value Health Care 97.3% Asset Allocation
Asset Class Value Cash 2.7% Equity 97.3% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMA12% ₹1,073 Cr 5,906,349 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB7% ₹651 Cr 700,754 Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | 5002576% ₹565 Cr 2,783,991 Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | 5000876% ₹551 Cr 4,095,054 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | DRREDDY5% ₹499 Cr 4,049,746 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Sep 20 | APOLLOHOSP5% ₹448 Cr 548,795 Mankind Pharma Ltd (Healthcare)
Equity, Since 30 Apr 23 | MANKIND4% ₹401 Cr 1,603,562 Sai Life Sciences Ltd (Healthcare)
Equity, Since 31 Dec 24 | SAILIFE4% ₹359 Cr 2,355,745
↓ -200,000 Ajanta Pharma Ltd (Healthcare)
Equity, Since 30 Apr 22 | 5323314% ₹331 Cr 913,918 GlaxoSmithKline Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Aug 22 | GLAXO3% ₹285 Cr 1,029,460 3. UTI Healthcare Fund
UTI Healthcare Fund
Growth Launch Date 28 Jun 99 NAV (30 Oct 26) ₹328.616 ↓ -0.45 (-0.14 %) Net Assets (Cr) ₹1,430 on 30 Sep 26 Category Equity - Sectoral AMC UTI Asset Management Company Ltd Rating ☆ Risk High Expense Ratio 2.26 Sharpe Ratio 0.78 Information Ratio 0.06 Alpha Ratio 0.86 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value 31 Oct 21 ₹10,000 31 Oct 22 ₹9,416 31 Oct 23 ₹10,985 31 Oct 24 ₹17,495 31 Oct 25 ₹17,846 31 Oct 26 ₹20,163 Returns for UTI Healthcare Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 30 Oct 26 Duration Returns 1 Month -1.3% 3 Month -1.6% 6 Month 12.3% 1 Year 12.4% 3 Year 22.3% 5 Year 15.1% 10 Year 15 Year Since launch 14.8% Historical performance (Yearly) on absolute basis
Year Returns 2025 -3.1% 2024 42.9% 2023 38.2% 2022 -12.3% 2021 19.1% 2020 67.4% 2019 1.2% 2018 -7.5% 2017 6.2% 2016 -9.7% Fund Manager information for UTI Healthcare Fund
Name Since Tenure Kamal Gada 2 May 22 4.42 Yr. Data below for UTI Healthcare Fund as on 30 Sep 26
Equity Sector Allocation
Sector Value Health Care 94.12% Asset Allocation
Asset Class Value Cash 5.88% Equity 94.12% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMA8% ₹109 Cr 600,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLAB6% ₹88 Cr 94,707 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | DRREDDY5% ₹75 Cr 607,098
↑ 153,955 Ajanta Pharma Ltd (Healthcare)
Equity, Since 31 Jul 17 | 5323315% ₹69 Cr 190,000 Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLAND4% ₹58 Cr 200,000
↑ 15,000 Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 May 21 | ALKEM4% ₹53 Cr 102,500
↑ 13,500 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 21 | APOLLOHOSP3% ₹43 Cr 53,000 Caplin Point Laboratories Ltd (Healthcare)
Equity, Since 31 Dec 23 | CAPLIPOINT3% ₹43 Cr 159,030
↓ -15,789 Global Health Ltd (Healthcare)
Equity, Since 31 Oct 24 | MEDANTA3% ₹42 Cr 310,000
↑ 35,710 Lupin Ltd (Healthcare)
Equity, Since 28 Feb 25 | 5002573% ₹41 Cr 203,834
Medical spending in India has projected to grow 9-12 per cent over the next five years. Further, the growth in domestic sales may increase because of coronavirus. To add more, in such a volatile phase, there are a few Mutual Funds that are performing well.
Speedy introduction of generic or new drugs into the market are in focus and it has expected to benefit the Indian Pharmaceutical companies.
Research Highlights for SBI Healthcare Opportunities Fund